A single administration of sgRubicon‐LNP reduced hepatic steatosis and lipid accumulation, regulated the glycerophospholipid metabolism pathway, and reduced CD36 expression, showcasing its potential to alleviate NAFLD. Here, CD36 is linked to Hepatic steatosis.